Salvianolic Acid B Inhibits Ang II-induced VSMC Proliferation in Vitro and Intimal Hyperplasia in Vivo by Downregulating MiR-146a Expression
Overview
Affiliations
Background: Salvianolic acid B (Sal B), a water-soluble compound extracted from Salvia miltiorrhiza that has been widely used to treat cardiovascular diseases for hundreds of years in China, exerts cardiovascular protection by multiple mechanisms. miR-146a is involved in vascular smooth muscle cell (VSMC) phenotypic modulation and proliferation. However, it has yet to be investigated whether the cardiovascular protective effect of Sal B is mediated by miR-146a.
Purpose: To determine the relationship among the cardiovascular protective effect of Sal B, miR-146a expression, and VSMC proliferation.
Methods: MTS assay and cell counting were performed to evaluate the effect of Ang II, Sal B and miR-146a on VSMC proliferation. The neointima hyperplasia was assessed by hematoxylin/eosin staining. qRT-PCR was used to detect the expression of miR-146a, KLF5, cyclin D1 and PCNA. Western blot analysis was used to detect the expressions of KLF5, cyclin D1 and PCNA after miR-20b-5p was knocked down or overexpressed in VSMC.
Results: Sal B suppressed intimal hyperplasia induced by carotid artery ligation and decreased Ang II-induced VSMC proliferation by down-regulating the positive cell-cycle regulators KLF5 and cyclin D1. Further experiments showed that VSMC proliferation and upregulation of KLF5 and cyclin D1 induced by Ang II were accompanied by elevated miR-146a level. Furthermore, overexpression of miR-146a promoted and knockdown of miR-146a reduced Ang II-induced VSMC proliferation and ameliorated intimal hyperplasia induced by carotid artery ligation. Sal B inhibited Ang II-induced VSMC proliferation by suppressing miR-146a expression.
Conclusion: Sal B inhibited Ang II-induced VSMC proliferation in vitro and intimal hyperplasia in vivo by downregulating miR-146a expression.
Zhang M, Zhang M, Chen H, Wang X, Zhao K, Li X Mediators Inflamm. 2024; 2024:4121166.
PMID: 38405620 PMC: 10890902. DOI: 10.1155/2024/4121166.
Li Z, Zhu J, Ouyang H Front Pharmacol. 2023; 14:1303012.
PMID: 38155904 PMC: 10754536. DOI: 10.3389/fphar.2023.1303012.
Yang Y, Huang S, Wang J, Nie X, Huang L, Li T Korean J Physiol Pharmacol. 2023; 28(1):39-48.
PMID: 38154963 PMC: 10762488. DOI: 10.4196/kjpp.2024.28.1.39.
Chen Y, He S, Zeng A, He S, Jin X, Li C Anal Cell Pathol (Amst). 2023; 2023:2677020.
PMID: 38028434 PMC: 10645495. DOI: 10.1155/2023/2677020.
Liu G, Tan L, Zhao X, Wang M, Zhang Z, Zhang J Front Pharmacol. 2023; 14:1283494.
PMID: 38026969 PMC: 10657887. DOI: 10.3389/fphar.2023.1283494.